MedTrace Logo

Azithromycin in Bronchiolitis Obliterans Syndrome

NCT01009619 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2011-10-03

Study results available
· View outcomes & findings →

Summary

Preventive treatment with azithromycin reduces the prevalence fo Bronchiolitis Obliterans Syndrome after lung transplantation.

Conditions

  • Bronchiolitis Obliterans Syndrome
  • Graft Rejection
  • Lymphocytic Bronchiolitis
  • Respiratory Infection

Interventions

DRUG

Azithromycin

Azithromycin 250 mg daily during 5 days followed by 250 mg three times a week on Mon., Wed. and Fri. during study-period.

DRUG

Placebo

Placebo once daily during 5 days, followed by one placebo three times a week on Mon., Wed. and Fri during rest of study-period.

Sponsors & Collaborators

  • University Hospital, Gasthuisberg

    collaborator OTHER

  • Fund for Scientific Research, Flanders, Belgium

    collaborator OTHER

  • KU Leuven

    lead OTHER

Principal Investigators

  • Geert M Verleden, Prof. Dr. · KULeuven and University Hospitals Leuven

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01009619 on ClinicalTrials.gov